Home ›
Breast Cancer Trials ›
NCT06085742
BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer
This is a non-randomized, single arm phase 2 trial of oral CMC based on conversion of doses that would be delivered with conventional metronomic CMF chemotherapy.
Trial Details
NCT ID NCT06085742
Phase PHASE2
Sponsor University of Illinois Chicago
Status RECRUITING
Cancer Type Breast Cancer
Interventions Cyclophosphamide Methotrexate Capecitabine
Locations (sample) Chicago, Illinois, United States|41.85003,-87.65005
Key Eligibility Criteria
I• Age ≥ 18 years of age at time of consent ECOG performance status 0, 1, or 2 Histologically confirmed invasive breast cancer documented by biopsy or surgical excision. Underwent potentially curative resection of primary breast tumor(s) with no gross residual local-regional disease (patients with microscopically po…
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Breast Cancer Trials on Trialify →